Drug Development Treatment Trials White Paper 
Conversations in Drug Development Trends
MARCH 20, 2024
In the increasingly advancing world of medicine, personalized care is a key factor that can progress your drug development efforts. One way to ensure customized disease management is to utilize pharmacogenomics (PGx) in your clinical trial. Reduces Trial Failures Oftentimes, clinical trials may fail due to a lack of efficacy.
PPD
MARCH 21, 2024
When participating in clinical trials, pediatric populations require distinct considerations for their safety and well-being — which can present unique challenges for drug developers. Five Strategies to Tailor Your Pediatric Clinical Trials to the Child’s Needs 1.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
OCTOBER 16, 2020
As pharma companies search for solutions to avoid cancelling or delaying clinical trials, virtualizing trials are fast becoming commonplace during the Covid-19 pandemic. With many nationwide and regional lockdowns coming into force, virtual clinical trials are proving to be an effective way to monitor patients remotely.
Conversations in Drug Development Trends
NOVEMBER 21, 2023
Since the advent of modern medicine, the scientific community has developed more than 3,000 drugs for thousands of diseases. Despite significant progress, there are more than 6,500 rare diseases without a single approved treatment. There are so many patients suffering from diseases that have no treatments.
Conversations in Drug Development Trends
MARCH 1, 2024
These designs facilitate streamlined trial logistics and centralized governance and create higher-quality data. Master protocols allow a trial to perform multiple tests on diverse patient populations or diseases under a unified design. Do you have various stakeholders invested in the success of your development programs?
Conversations in Drug Development Trends
AUGUST 14, 2024
By: Simran Padam, Medical Director, Medical Affairs Personalized treatment approaches have emerged as pivotal in improving outcomes for hematological cancers. Hematological cancer cells can also develop resistance to therapies over time, reducing treatment effectiveness.
Conversations in Drug Development Trends
MARCH 12, 2024
From their use in risk and safety assessments to patient screening and treatment efficacy, biomarkers offer minimally invasive, objective data. For a more in-depth look at biomarkers, check out our white paper. Deviations from established baseline values provide insights into treatment response in certain cancer indications.
Expert insights. Personalized for you.
52 
Let's personalize your content